Inebilizumab

Generic Name
Inebilizumab
Brand Names
Uplizna 3 Vial Kit, Uplizna
Drug Type
Biotech
Chemical Formula
-
CAS Number
1299440-37-1
Unique Ingredient Identifier
74T7185BMM
Background

Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis optica spectrum disorder (NMOSD). Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against the broadly expressed B-cell surface...

Indication

Inebilizumab is indicated for the treatment of aquaporin-4 (AQP4) immunoglobulin-positive (AQP4-IgG) neuromyelitis optica spectrum disorder (NMOSD) in adult patients.

Associated Conditions
Neuromyelitis Optica Spectrum Disorders
Associated Therapies
-
Clinical Trials
Related News

A Phase 2a Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

Phase 2
Not yet recruiting
Conditions
Systemic Lupus Erythematosus
Interventions
Drug: Inebilizumab
Drug: Blinatumomab
First Posted Date
2024-08-26
Last Posted Date
2024-12-06
Lead Sponsor
Amgen
Target Recruit Count
50
Registration Number
NCT06570798
Locations
🇺🇸

Homestead Associates In Research Inc, Homestead, Florida, United States

🇺🇸

Vida Medical Research, Hialeah, Florida, United States

🇺🇸

Vitaly Clinical Research, Miami, Florida, United States

A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders

Phase 4
Not yet recruiting
Conditions
Neuromyelitis Optica Spectrum Disorders
Interventions
Drug: Inebilizumab
First Posted Date
2024-01-18
Last Posted Date
2024-01-18
Lead Sponsor
Hansoh BioMedical R&D Company
Target Recruit Count
33
Registration Number
NCT06212245
Locations
🇨🇳

IRB of Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China

Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)

First Posted Date
2023-12-22
Last Posted Date
2024-10-31
Lead Sponsor
Amgen
Target Recruit Count
30
Registration Number
NCT06180278
Locations
🇵🇱

Uniwersyteckie Centrum Kliniczne WUM, Warszawa, Mazowieckie, Poland

🇺🇸

Baylor College of Medicine, Houston, Texas, United States

🇭🇺

Szegedi Tudományegyetem, ÁOK, Szent-Györgyi Albert Klinikai Központ, Szeged, Csongrád, Hungary

and more 7 locations

Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders

First Posted Date
2023-10-05
Last Posted Date
2023-10-05
Lead Sponsor
Feng Jinzhou
Target Recruit Count
80
Registration Number
NCT06068829

Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders

First Posted Date
2023-06-06
Last Posted Date
2024-06-24
Lead Sponsor
Xuanwu Hospital, Beijing
Target Recruit Count
50
Registration Number
NCT05891379
Locations
🇨🇳

Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China

Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

Phase 2
Recruiting
Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
Drug: Inebilizumab
First Posted Date
2022-09-22
Last Posted Date
2024-10-26
Lead Sponsor
Amgen
Target Recruit Count
15
Registration Number
NCT05549258
Locations
🇨🇦

Hospital For Sick Children, Toronto, Ontario, Canada

🇺🇸

Loma Linda University Children's Hospital, Loma Linda, California, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 14 locations

A Study of MT-0551 in Patients With Systemic Sclerosis

Phase 3
Recruiting
Conditions
Systemic Sclerosis
Interventions
Drug: Inebilizumab
Drug: Placebo
First Posted Date
2022-01-20
Last Posted Date
2024-07-05
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
80
Registration Number
NCT05198557
Locations
🇯🇵

University of Fukui Hospital, Yoshida-gun, Fukui, Japan

🇯🇵

Kanazawa University Hospital, Kanazawa, Ishikawa, Japan

🇯🇵

St. Marianna University Hospital, Kawasaki-shi, Kanagawa, Japan

and more 1 locations

A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease

Phase 3
Active, not recruiting
Conditions
IgG4 Related Disease
Interventions
Drug: Inebilizumab
Other: Placebo
First Posted Date
2020-09-07
Last Posted Date
2024-11-05
Lead Sponsor
Amgen
Target Recruit Count
135
Registration Number
NCT04540497
Locations
🇬🇧

Viela Bio Investigative Site, Oxford, United Kingdom

🇪🇸

Viela Bio Investigative Site 2, Barcelona, Spain

🇨🇳

Viela Bio Investigative Site 1, Beijing, China

and more 4 locations

Myasthenia Gravis Inebilizumab Trial

Phase 3
Active, not recruiting
Conditions
Myasthenia Gravis
Interventions
Drug: IV Placebo
Drug: inebilizumab
First Posted Date
2020-08-24
Last Posted Date
2024-10-29
Lead Sponsor
Amgen
Target Recruit Count
238
Registration Number
NCT04524273
Locations
🇨🇳

Viela Bio Investigative Site - 4006, Shanghai, China

🇨🇳

Viela Bio Investigative Site - 4004, Tianjin, China

🇨🇳

Viela Bio Investigative Site -4607, Taipei, Taiwan

and more 100 locations

The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

First Posted Date
2020-05-04
Last Posted Date
2024-08-27
Lead Sponsor
University of Utah
Target Recruit Count
116
Registration Number
NCT04372615
Locations
🇺🇸

University of Iowa, Iowa City, Iowa, United States

🇺🇸

University of Rochester, Rochester, New York, United States

🇳🇱

Erasmus Medical University Center, Rotterdam, Netherlands

and more 25 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy